Telo Genomics Corp. is a molecular diagnostics company focused on developing personalized treatment plans through predictive technology. While it boasts a strong liquidity position with a current ratio of 2.25 and no debt, its financial health is concerning, highlighted by extremely negative ROE and ROA figures. The market cap of $5.52 million and low stock price suggest potential undervaluation, but the lack of profitability raises red flags for investors. Overall, while the company has a solid foundation, its financial metrics indicate significant challenges that need addressing.
Loading financial metrics...
Company has $789K in cash but burned $582K last quarter. At this burn rate, only 1.4 quarters of runway remain without additional financing.
Company posted a loss of $-2.7M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $2.3M over the last year.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Strong liquidity position with current ratio of 2.3x.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Diagnostics & Research companies of a similar size
Based on 2025-FY (June 30, 2025)